Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INSULET CORPORATION

(PODD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insulet Corporation’S Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 Years

06/26/2021 | 04:00pm EDT

Insulet Corporation announced promising results from its latest pivotal trial for the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in very young children. Omnipod 5, the world’s first tubeless, wearable automated insulin delivery (AID) system that continuously adapts insulin delivery based on glucose levels and trends, significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years with type 1 diabetes. These pivotal study data from the preschool age group were presented at the American Diabetes Association (ADA) Virtual 81st Scientific Sessions. Omnipod 5 Preschool Pivotal Study Overview - Insulet enrolled a group of 80 preschool aged children across 10 U.S. sites for this study. The participants, who were between 2 and 5.9 years of age with an HbA1c of under 10.0%, used Omnipod 5 at home for a period of 3 months after a 14-day period using their standard therapy, which included either pump therapy or multiple daily injections (MDI). The children were unrestricted in eating and exercise throughout the study. The study showed an overall reduction in HbA1c from an average of 7.4% to 6.9%, and a significant increase in time in range (70-180 mg/dL), from an average of 57.2% to 68.1%, or an additional 2.6 hours per day. Median time in hypoglycemia (


© S&P Capital IQ 2021
All news about INSULET CORPORATION
08/26INSULET : to Present at Upcoming Investor Conferences
BU
08/19INSULET : Significant Insider Selling in Shares of Insulet (PODD) Continues
MT
08/19INSIDER TRENDS : Insulet Insider Exercises Options in Face of 90-Day Selling Trend
MT
08/18INSIDER TRENDS : Insulet Insider Extends 90-Day Selling Trend
MT
08/16INSULET : Says FDA Clears Use of Its Insulin Management Products With Eli Lilly's Lyumjev ..
MT
08/16INSULET : Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® P..
BU
08/16Insulet Corporation Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use wi..
CI
08/11INSULET : Introduces Omnipod DASH® System at Australasian Diabetes Congress
BU
08/11Insulet Introduces Omnipod DASH System at Australasian Diabetes Congress
CI
08/10INSIDER TRENDS : 90-Day Insider Buying Trend Scaled Back with Sale of Insulet Shares
MT
More news
Analyst Recommendations on INSULET CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 085 M - -
Net income 2021 21,8 M - -
Net Debt 2021 260 M - -
P/E ratio 2021 866x
Yield 2021 -
Capitalization 20 015 M 20 015 M -
EV / Sales 2021 18,7x
EV / Sales 2022 15,4x
Nbr of Employees 1 900
Free-Float 99,6%
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 290,60 $
Average target price 285,37 $
Spread / Average Target -1,80%
EPS Revisions
Managers and Directors
Shacey Petrovic President, Chief Executive Officer & Director
Wayde Dwight McMillan Chief Financial Officer, Treasurer & Executive VP
Timothy J. Scannell Independent Chairman
Trang Ly Senior Vice President & Medical Director
Charles Alpuche Chief Operations Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INSULET CORPORATION12.66%20 015
ABBOTT LABORATORIES14.44%222 134
MEDTRONIC PLC11.52%175 817
BECTON, DICKINSON AND COMPANY1.44%72 895
HOYA CORPORATION28.03%61 174
SARTORIUS STEDIM BIOTECH83.38%57 768